FDA Approves Crizotinib for ALK-Positive Inflammatory Myofibroblastic Tumors

FDA Approves Crizotinib for ALK-Positive Inflammatory Myofibroblastic Tumors

header-info

On July 14, the U.S. Food and Drug Administration (FDA) approved crizotinib (Xalkori) for adult and pediatric patients aged 1 year and older with unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors.